2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds

US8673894B2 · kind B2 · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• David Banner · Basel, CH
• Wolfgang Guba · Memmingen, DE
• Hans Hilpert · Reinach, CH
• Roland Humm · Auggen, DE
• Harald Mauser · Riehen, CH
• Alexander V. Mayweg · Basel, CH
• Robert Narquizian · La Valette-du-Var, FR
• Eoin Power · Siena, IT
• Mark Rogers-Evans · Bottmingen, CH
• Didier Rombach · Mulhouse, FR
• Thomas Woltering · Freiburg (Elbe), DE
• Wolfgang Wostl · Weil am Rhein, DE

Key dates

• Filing date: Apr 28, 2011
• Grant date: Mar 18, 2014
• Expiry date: Nov 2, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to compounds of the formulawherein A, B and R1 to R7 are as described below, or to pharmaceutically acceptable salts thereof. These compounds are BACE1 and/or BACE2 inhibitors and can be used as medicaments for the therapeutic and/or prophylactic treatment of diseases such as Alzheimer's disease, diabetes, particularly type 2 diabetes, and other metabolic disorders.